Shares of ArQule, Inc. ARQL are galloping toward a multiyear high in the wake of the presentation of a clinical trial readout.
What Happened
The small-cap biotech announced preliminary results from a Phase 1 dose escalation study for ARQ 531 in patients with relapsed or refractory hematologic malignancies that showed the candidate was well-tolerated in a 65 mg once-daily dose.
ARQ 531 is an orally bioavailable reversible dual inhibitor of both wild type and C481S-mutant Bruton's tyrosine kinase, or BTK.
The data comes from an ongoing Phase 1 study that included eight cohorts at dose levels of 5, 10, 15, 20, 30, 45, 65 and 75 mg once-daily in patients with relapsed or refractory chronic lymphocytic leukemia, or CLL; small lymphocytic leukemia, or SLL; Richter's Transformation; Waldenstrom macroglobulinemia and other B-cell non-Hodgkin lymphomas.
The study showed that ARQ 531 is tolerated through 65 mg once-daily doses, and pharmacokinetic data demonstrated a steady-state mean Cmin of above 1 µM in patients receiving doses higher than 45 mg, with the plasma half-life at 20-30 hours.
Doses above 20-30 mg lead to complete pBTK inhibition and substantial CCL3 suppression, according to ArQule.
The study also showed dose-dependent anti-tumor activity, with an overall response rate of 66% in heavily pre-treated CLL patients from cohort 7 who have the BTK-C481S mutation.
"The data presented in this poster provide compelling clinical proof-of-concept for this novel class of reversible BTK inhibitors," Jennifer Woyach, the lead study investigator, said in a statement.
The data was presented as a poster at the 2019 European Hematology Association annual meeting in Amsterdam, the Netherlands.
What Next
ArQule said it will look ahead to finalize the recommended Phase 2 dose and advance ARQ 531 into later-stage trials across multiple indications as a single agent and as a combination therapy.
The stock was rising by 37.2% to $8.63 at the time of publication Friday.
Related Links:
Savara Stock In Freefall As Rare Pulmonary Autoimmune Disorder Drug Fumbles Late-Stage Trial
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
